biomarker-trends-header.png

Fail Early, Fail Fast - And Increase Likelihood-of-Approval

What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how it affects the industry.

The First Ever Blood Biomarker For Multiple Sclerosis Discovered.

Huge news coming in the world of health and science as the first ever blood biomarker for Multiple Sclerosis (MS) has been discovered.

Top Blog Posts of 2016

by Seth Taylor | Jan 26, 2017 | Insider, Company News

As we ramp for a great 2017 we are looking back on what we did in 2016. In that spirit, here are the top 5 blog posts of 2016 by views.

Biomarkers and The Adoption Cycle: Where are we now?

This week we introduced the correlation between a company's biomarker coverage in their clinical trial pipeline and their Likelihood of Approval. After showing correlation between approval and biomarker use, we wanted to know more about a company’s biomarker use year over year. As we dove deeper ...

Chart of the Week: Phase 3 LOA Vs Biomarker Coverage Percent

This week’s Chart of the Week demonstrates recent research on the correlation between the Biomarker Coverage Percent in a company's pipeline and the Company's Phase 3 Likelihood of Approval. This chart depicts how as a company increases their number of trials utilizing biomarkers, they will also ...

   

December

Webinar: 

Pharmacovigilance and Safety Biomarkers

RECORDING
New Call-to-action
FREE REPORT

Subscribe for Updates

Download our Free IVD Trends Report